DMK Pharmaceuticals Corp
OTC:DMKPQ
DMK Pharmaceuticals Corp
OTC:DMKPQ
Price:
0.0001
USD
Market Cap:
$10
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
DMK Pharmaceuticals Corp
OTC:DMKPQ
|
US |
|
Comvita Ltd
NZX:CVT
|
NZ |
|
D
|
Duke Energy Corp
F:D2MN
|
US |
|
AGNC Investment Corp
NASDAQ:AGNC
|
US |
|
H
|
Hexing Electrical Co Ltd
SSE:603556
|
CN |
|
I
|
IRPC PCL
SET:IRPC
|
TH |
|
N
|
NEC Corp
XHAM:NEC1
|
JP |
|
Orizon Valorizacao de Residuos SA
BOVESPA:ORVR3
|
BR |
|
MAG Silver Corp
TSX:MAG
|
CA |
|
V
|
Vikas Lifecare Ltd
NSE:VIKASLIFE
|
IN |
|
American International Group Inc
NYSE:AIG
|
US |
|
Z
|
Zhi Sheng Group Holdings Ltd
HKEX:8370
|
CN |
|
T
|
Tamilnadu Telecommunication Ltd
BSE:523419
|
IN |
|
Permanent TSB Group Holdings PLC
LSE:PTSB
|
IE |
|
Amlogic Shanghai Co Ltd
SSE:688099
|
CN |
|
L
|
Life Healthcare Group Ltd
HKEX:928
|
HK |
Multiples-Based Value
There is not enough data to reliably calculate the multiples-based value of DMKPQ.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
DMKPQ
Multiples-Based Value
Base Case
Not Available
Multiples Across Competitors
DMKPQ Competitors Multiples
DMK Pharmaceuticals Corp Competitors
DMK Pharmaceuticals Corp Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
DMK Pharmaceuticals Corp
OTC:DMKPQ
|
10 USD | 0 | -0 | 0.3 | 0.3 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
847.5B USD | 12.9 | 40.7 | 27.5 | 29.4 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
576.1B USD | 6.2 | 21.7 | 15.1 | 18.5 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4 | 19.3 | 11.5 | 12.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
294.3B USD | 4.6 | 16.3 | 10.1 | 12.3 | |
| CH |
|
Novartis AG
SIX:NOVN
|
229.3B CHF | 5.2 | 21.1 | 13 | 16.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
214.5B GBP | 5.1 | 29.1 | 16.1 | 22.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK | 3.3 | 9.8 | 7.3 | 8.6 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
156.8B USD | 2.5 | 20 | 7.7 | 10.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119.6B USD | 2.5 | 16.8 | 7.1 | 8.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
